Pemirolast Brand Name– Alamast
What is Pemirolast
Pemirolast is a prescription ophthalmic product approved for relief of ophthalmic pruritis due to allergic conjunctivitis.
Pemirolast is a mast cell stabilizer similar to cromolyn that inhibits the antigen-induced release of inflammatory mediators.
Pemirolast is being investigated as a oral mast cell stabilizer, given twice daily for the treatment of allergic asthma and seasonal allergic rhinitis.
Alamast(TM) 0.1%, a topical ophthalmic solution, was granted FDA approval for the treatment of allergic conjunctivitis on September 24, 1999.
Indications
- allergic conjunctivitis
For the prevention of ocular pruritus due to allergic conjunctivitis
Side Effects
- foreign body sensation
- headache
- ocular irritation
- rhinitis
- xerophthalmia
The most frequent (10—25%) adverse effects associated with pemirolast ophthalmic solution in clinical studies lasting up to 17 weeks were generally mild and included: headache, rhinitis, and cold/flu symptoms (not specified). Some of these events were similar to the underlying disease being studied. Less frequent (< 5%) ocular adverse reactions included: ocular irritation (ocular discomfort or burning), xerophthalmia (dry eye), and foreign body sensation. Other (non-ocular) less frequent (< 5%) reactions included: allergy, back pain, bronchitis, cough, dysmenorrhea, fever, sneezing, nasal congestion, and sinusitis.
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- children
- contact lenses
- infants
- neonates
- pregnancy
Interactions
There are no drug interactions associated with Pemirolast products.
